Edmonton, Alberta, Canada
March 17, 2010

Innovotech Inc. (TSX VENTURE:IOT) today announced its audited financial and operational results for the year ended December 31, 2009.

Highlights:

• Highest revenue year in Company's history.
• First commercial sale of bioFILM PA(TM) kit.
• Commercial Agreement for Agress(TM) signed with Syngenta, the world'slargest seed treatment company.
• Field trials of Agress(TM) demonstrate expanded scope of use.

"Strong growth in contract research propelled the Company to its best revenue year ever. Combined with the first commercial sale of bioFILM PA(TM) kit in early 2010, we are optimistic that revenues will continue to grow," says Dr. James Timourian, Chief Financial Officer. "While delays in regulatory approval with both the Environmental Protection Agency (US) and the Pest Management Regulatory Agency (Canada) have slowed market entry of its lead agricultural product, Agress(TM), the Company, with support from its commercial partner, is working to overcome these barriers in the quickest possible time frame. In addition, results from field and greenhouse trials conducted during 2009 show broad potential for Agress(TM) in a variety of high value-added crops such as potatoes, vegetables and fruits. A plan for obtaining regulatory approval for these new uses is being developed. This will greatly expand the already encouraging revenue potential of Agress(TM)."

The importance of biofilms in human health, agriculture and industry continues to be recognized. The Company recently signed Material Transfer Agreements with several multinational medical device companies to incorporate a patented Innovotech antimicrobial material into catheters and other medical devices. The companies intend to pursue commercial agreements once initial validation work is complete.
 

Innovotech is a product development company focusing on the development of solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are protected communities of microorganisms which are very common and very difficult to treat due to their inherent resistance. They have been implicated in a host of devastating infections in agriculture, human health and industry. No diagnostics or antibiotics are currently approved for use in infections involving biofilms.

Website: http://www.innovotech.ca

Published: March 17, 2010